In Re: Purdue Pharma L.P.

District Court, S.D. New York·Decided July 25, 2025·No. 7:25-cv-00484·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ----------------------------------------------------------------x In re

PURDUE PHARMA L.P., et al.,

Debtors. ----------------------------------------------------------------x AMANDA MORALES,

Appellant, OPINION & ORDER

– against – No. 25-CV-484 (CS) PURDUE PHARMA L.P., et al.,

Appellees. ----------------------------------------------------------------x

Appearances:

Amanda Morales Bernalillo, New Mexico Pro Se Appellant

Marshall S. Huebner Benjamin S. Kaminetzky James I. McClammy Eli J. Vonnegut Davis Polk & Wardwell LLP New York, New York Counsel for Debtors-Appellees and Debtors in Possession

Seibel, J. Before the Court is the appeal of Appellant Amanda Morales from a December 12, 2024 order of Judge Sean H. Lane of the United States Bankruptcy Court for the Southern District of New York, in the Chapter 11 bankruptcy proceeding captioned In re Purdue Pharma L.P., et al., No. 19-BK-23649 (Bankr. S.D.N.Y.). The oral order of that date, which was memorialized in a written Order dated January 9, 2025, (Bankr. Dkt. No. 7094), denied Appellant’s motion for class certification, (see Bankr. Dkt. No. 7042 (the “December 12 Transcript”) at 16:24-17:15).1 For the following reasons, the Bankruptcy Court’s Order is affirmed. I. BACKGROUND I assume the parties’ familiarity with the underlying bankruptcy proceedings, and I recite only those facts relevant to the disposition of this matter.

In 2010, Appellant’s father died from serotonin syndrome, “as a result of ‘interactions and risks from concomitant use with benzodiazepines and other CNS depressants’ and OxyContin.” (Bankr. Dkt. No. 6869 (“Am. Class Cert. Mot.”) at 1.) Appellant alleges Purdue Pharma, L.P. (“Debtors-Appellees”) did not adequately warn about the danger of such drug interactions until 2016, when Debtors-Appellees added these risks to the OxyContin box label warning. Id. As a result, since at least 2021, Appellant has participated as a pro se litigant in the bankruptcy action filed by various U.S.-based Purdue Pharma entities on September 15, 2019, (Bankr. Dkt. No. 1), and has filed several motions and letters with the Bankruptcy Court, (see, e.g., Bankr. Dkt. Nos. 3191, 3994, 4289, 5782). On October 14, 2024, Appellant filed a Motion for Class Certification, seeking

certification, pursuant to Rule 23 of the Federal Rules of Civil Procedure, of a class of personal injury claimants divided into two subclasses. (Bankr. Dkt. No. 6811.) The proposed subclasses were: (1) “personal injury/death related to addiction and overdose and abatement programs,” and (2) “[w]rongful death and personal injury from failing to warn of known drug interactions or unlisted side effects/adverse effects.” (Am. Class Cert. Mot. at 2.) Appellant sought

1 Citations to “Bankr. Dkt. No.” refer to entries on the Bankruptcy Court’s docket, No. 19-BK-23649. Citations to “ECF No.” refer to entries on this Court’s docket for this case, No. 25-CV-484. All citations to page numbers of such documents refer to the page numbers generated by the respective Court’s Electronic Case Filing System. certification of the subclasses because “[t]he personal injury class of creditors is too general and the committee of unsecured creditors hasn’t fairly represented unrelated claims like [hers] that aren’t related to addiction or the opioid crisis.” (Bankr. Dkt. No. 6813 at 5; see Am. Class Cert. Mot. at 2.) Debtors-Appellees objected to Appellant’s request for class certification on December 5, 2024. (Bankr. Dkt. No. 6990.)

On December 12, 2024, the Bankruptcy Court held a hearing and denied the motion because “a pro se party such as Ms. Morales can’t act as a class representative.” (December 12 Transcript at 16:24-17:15.) On January 9, 2025, the Bankruptcy Court issued a written Order denying the request for class certification for the reasons stated at the December 12 hearing. (Bankr. Dkt. No. 7094.) Ms. Morales timely appealed on January 16, 2025. (ECF No. 1 (“Notice of Appeal”).)2 II. LEGAL STANDARD This Court has jurisdiction pursuant to 28 U.S.C. § 158(a)(1) to hear appeals from final judgments, orders, and decrees of a bankruptcy court. “This Court may affirm, modify, or reverse a bankruptcy judge’s judgment, order, or decree or remand with instructions for further proceedings.” In re Bernard L. Madoff Inv. Sec., LLC, No. 15-CV-1151, 2016 WL 183492, at *8

(S.D.N.Y. Jan. 14, 2016), aff’d, 697 F. App’x 708 (2d Cir. 2017) (summary order).3 “A district court reviews a bankruptcy court’s conclusions of law de novo, its discretionary decisions for abuse of discretion, and its findings of fact for clear error.” In re

2 Although the appeal was not docketed with this Court until January 16, 2025, Appellant filed her Notice of Appeal in the bankruptcy action on December 24, 2024. (See Bankr. Dkt. No. 7062.)

3 Unless otherwise noted, case quotations omit all internal quotation marks, citations, alterations, and footnotes. The Court will provide Appellant with copies of unreported cases cited in this Opinion. Depietto, No. 20-CV-8043, 2021 WL 3287416, at *4 (S.D.N.Y. Aug. 2, 2021). “Bankruptcy court decisions to deny a request . . . to certify a class are reviewed for abuse of discretion.” In re BGI, Inc., No. 11-10614, 2012 WL 5392208, at *5 (Bankr. S.D.N.Y. Nov. 2, 2012); see In re Bally Total Fitness of Greater N.Y., Inc., 411 B.R. 142, 145 (S.D.N.Y. 2009) (reviewing bankruptcy court’s denial of motion for class certification for abuse of discretion).

Under the abuse of discretion standard, [r]elief from the district court is appropriate only when the bankruptcy court’s decision either (i) rests on an error of law (such as application of the wrong legal principle) or a clearly erroneous factual finding, or (ii) though not necessarily the product of legal error or clearly erroneous factual finding, cannot be located within the range of permissible decisions. In re Refco Inc., No. 07-CV-10708, 2009 WL 2355808, at *2 (S.D.N.Y. July 29, 2009); see S.E.C. v. Bankosky, 716 F.3d 45, 47 (2d Cir. 2013) (reviewing court “will reverse [for abuse of discretion] only if [it] ha[s] a definite and firm conviction that the court below committed a clear error of judgment in the conclusion that it reached upon a weighing of the relevant factors”). This standard is “highly deferential,” In re Lehman Bros. Holdings, Inc., 435 B.R. 122, 131 (S.D.N.Y. 2010), aff’d sub nom. Suncal Cmtys. I LLC v. Lehman Com. Paper, Inc., 402 F. App’x 634 (2d Cir. 2010) (summary order), and “[m]atters concerning decisions within the discretion of bankruptcy judges will not be disturbed by the district court unless the district court finds that no reasonable [person] could agree with the bankruptcy judge’s decision,” In re Integrated Res., Inc., 157 B.R. 66, 72 (S.D.N.Y. 1993); see In re Enron Corp., 419 F.3d 115, 124 (2d Cir. 2005). Appellant appeals pro se. Accordingly, the Court is required to accord her “special solicitude,” In re Saint Vincents Cath. Med. Ctrs. of N.Y., No. 11-CV-9431, 2012 WL 4462030, at *1 n.1 (S.D.N.Y. Sept. 27, 2012), and construe her submissions “liberally to raise the strongest arguments that they suggest,” Amelio v. Piazza, No. 19-CV-5944, 2020 WL 5535241, at *3 (S.D.N.Y. Sept. 15, 2020). III.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re: Purdue Pharma L.P., (S.D.N.Y. 2025).

In Re: Purdue Pharma L.P. (In Re: Purdue Pharma L.P.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related